Impaired Cardiometabolic Responses to Glucagon-Like Peptide 1 in Obesity and Type 2 Diabetes Mellitus

dc.contributor.authorMoberly, Steven P.
dc.contributor.authorMather, Kieren J.
dc.contributor.authorBerwick, Zachary C.
dc.contributor.authorOwen, Meredith K.
dc.contributor.authorGoodwill, Adam G.
dc.contributor.authorCasalini, Eli D.
dc.contributor.authorHutchins, Gary D.
dc.contributor.authorGreen, Mark A.
dc.contributor.authorNg, Yen
dc.contributor.authorConsidine, Robert V.
dc.contributor.authorPerry, Kevin M.
dc.contributor.authorChisholm, Robin L.
dc.contributor.authorTune, Johnathan D.
dc.contributor.departmentCellular and Integrative Physiology, School of Medicine
dc.date.accessioned2025-05-07T11:45:22Z
dc.date.available2025-05-07T11:45:22Z
dc.date.issued2013
dc.description.abstractGlucagon-like peptide 1 (GLP-1) has insulin-like effects on myocardial glucose uptake which may contribute to its beneficial effects in the setting of myocardial ischemia. Whether these effects are different in the setting of obesity or type 2 diabetes (T2DM) requires investigation. We examined the cardiometabolic actions of GLP-1 (7-36) in lean and obese/T2DM humans, and in lean and obese Ossabaw swine. GLP-1 significantly augmented myocardial glucose uptake under resting conditions in lean humans, but this effect was impaired in T2DM. This observation was confirmed and extended in swine, where GLP-1 effects to augment myocardial glucose uptake during exercise were seen in lean but not in obese swine. GLP-1 did not increase myocardial oxygen consumption or blood flow in humans or in swine. Impaired myocardial responsiveness to GLP-1 in obesity was not associated with any apparent alterations in myocardial or coronary GLP1-R expression. No evidence for GLP-1-mediated activation of cAMP/PKA or AMPK signaling in lean or obese hearts was observed. GLP-1 treatment augmented p38-MAPK activity in lean, but not obese cardiac tissue. Taken together, these data provide novel evidence indicating that the cardiometabolic effects of GLP-1 are attenuated in obesity and T2DM, via mechanisms that may involve impaired p38-MAPK signaling.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationMoberly SP, Mather KJ, Berwick ZC, et al. Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol. 2013;108(4):365. doi:10.1007/s00395-013-0365-x
dc.identifier.urihttps://hdl.handle.net/1805/47852
dc.language.isoen_US
dc.publisherSpringer
dc.relation.isversionof10.1007/s00395-013-0365-x
dc.relation.journalBasic Research in Cardiology
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectObesity
dc.subjectDiabetes
dc.subjectGLP-1
dc.subjectCardiac
dc.subjectGlucose
dc.subjectMetabolism
dc.titleImpaired Cardiometabolic Responses to Glucagon-Like Peptide 1 in Obesity and Type 2 Diabetes Mellitus
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Moberly2013Impaired-AAM.pdf
Size:
3.07 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: